Monday, January 25, 2021
Home Latest Pharma-News AbbVie to present Ibrutinib (IMBRUVICA®) plus venetoclax (VENCLEXTA®/ VENCLYXTO®) , in...

AbbVie to present Ibrutinib (IMBRUVICA®) plus venetoclax (VENCLEXTA®/ VENCLYXTO®) , in American Society of Hematology (ASH) Annual Meeting for the treatment of Leukemias, Lymphomas and Other Blood Cancers

Nov 21, 2019 : AbbVie, a research-based global biopharmaceutical company announced that between Dec 7- 10  in American Society of Hematology (ASH) Annual Meeting & Exposition,  in Orlando more than 40 abstracts, including 18 oral presentations will be presented that include presentations on Ibrutinib (IMBRUVICA®) plus venetoclax (VENCLEXTA®/VENCLYXTO®) , which helps improving  the lives of people living with various difficult-to-treat blood cancers.

IMBRUVICA (ibrutinib)  blocks a protein called Bruton’s tyrosine kinase (BTK). It is an oral, once-daily medicine that works in a different way than chemotherapy.

- Advertisement -

VENCLEXTA®/VENCLYXTO® (venetoclax) selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. VENCLEXTA/VENCLYXTO targets the BCL-2 protein and helps to restore the apoptosis process. https://news.abbvie.com/news/press-releases/abbvie-to-present-latest-clinical-research-in-treatment-leukemias-lymphomas-and-other-blood-cancers-at-2019-ash-annual-meeting.htm

LEAVE A REPLY

Please enter your comment!
Please enter your name here

eleven − seven =

Most Popular

What is the process for Submission of Synopsis?

1.1 a. "Prior to submission of a thesis synopsis, a comprehensive assessment of the research work should be carried out by a...

COVAX Announces new agreement, plans for first deliveries

January 22, 2021: COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income...

FDA Approves OPDIVO® with CABOMETYX® as First-line Treatment for advanced Renal Cell Carcinoma

22 Jan 2021:  Bristol Myers Squibb announced that OPDIVO®(nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks...

FDA granted approval of Cabenuva and Vocabria to ViiV Healthcare for HIV

January 21, 2021: "The U.S. FDA approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human...